S&P 500 falls on pressure from retail stocks, weak jobless claims
On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Jasper Therapeutics (NASDAQ:JSPR) following the company’s fourth-quarter financial results. Jasper Therapeutics reported a net loss of $1.62 per basic and diluted share for the quarter ending in 2024. According to InvestingPro data, the company’s financial health score stands at 1.74, indicating WEAK overall conditions, with analysts setting price targets ranging from $38 to $80. In light of the recent earnings report and company guidance, Cantor Fitzgerald’s analysts have revised their financial model for Jasper Therapeutics.
The analysts at Cantor Fitzgerald have adjusted their 2025 earnings per share (EPS) estimates for Jasper Therapeutics. This revision comes after incorporating the actual earnings from the fourth quarter of 2024 and aligning the 2025 operating expense forecasts with the company’s guidance. The updated model reflects changes in the anticipated operating expenses for the upcoming year. InvestingPro reveals that 2 analysts have recently revised their earnings downwards for the upcoming period, with the EPS forecast for 2025 at -$7.23.
Jasper Therapeutics concluded the fourth quarter of 2024 with a strong cash position, reporting $72 million in cash and cash equivalents. This financial standing is expected to support the company’s operations moving forward. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, with a healthy current ratio of 4.98, though it’s quickly burning through available cash.
The reaffirmation of the Overweight rating by Cantor Fitzgerald indicates their positive outlook on Jasper Therapeutics’ stock. This outlook is based on the company’s current financial health and the adjustments made to the future earnings projections.
Investors monitoring Jasper Therapeutics will take note of Cantor Fitzgerald’s continued confidence in the stock. The firm’s analysis and rating are based on the company’s latest financial results and guidance, providing a snapshot of Jasper Therapeutics’ current and projected performance.
In other recent news, Jasper Therapeutics is preparing to present data from its Phase 1b/2a BEACON study on briquilimab at the upcoming American Academy of Dermatology Annual Meeting. The study focuses on briquilimab’s effects on adults with chronic spontaneous urticaria, revealing a rapid and meaningful reduction in disease activity. Meanwhile, JMP Securities has maintained its Market Outperform rating and a $70 price target on Jasper Therapeutics, highlighting a cautiously optimistic view of briquilimab’s market potential. In contrast, RBC Capital Markets has reduced its price target for Jasper to $48, citing initial BEACON study data but retaining an Outperform rating due to positive efficacy signs at a 240 mg dose.
BTIG also adjusted its price target to $64 from $90, while maintaining a Buy rating, acknowledging briquilimab’s efficacy and early safety profile. The BEACON study’s data indicated a 100% complete response rate at the 240mg dose, although concerns about safety and small sample size persist. Additionally, Citi’s analysis of Jasper’s data suggests the findings do not pose a significant threat to Celldex Therapeutics (NASDAQ:CLDX), with Citi maintaining a $70 price target on Celldex. Jasper Therapeutics plans to further develop briquilimab, with a registrational CSU program anticipated in the latter half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.